Peptide · Investigational peptide

AOD-9604

Research peptide

Aliases · hGH fragment 176-191 · AOD9604 · AOD 9604 · Tyr-hGH177-191

An investigational modified growth-hormone fragment that reached obesity trials but did not become an approved weight-loss medicine.

Human

1/5

Animal

3/5

In-vitro

0/5

Safety

0/5

Last reviewed · 7/11/2026

Compare with another peptide →

Last reviewed7/11/2026

Evidence statusEvidence in progress

Published references1

Trust signal panel

Evidence & safety

Human evidence
n/a
Animal evidence
n/a
Mechanistic
n/a
Safety knowledge
n/a
Editorial confidence
5/5

View in knowledge graph →See this peptide connected to conditions & mechanisms

Evidence Snapshot

Evidence snapshot · 4 verified refs

Overall: 3/5Moderate certainty (with caveats)
Human: 1/5Only review or summary sources indexed (not counted as primary human evidence)
Animal: 3/5Multiple animal studies
In-vitro: 0/5None identified
Safety: 0/5None identified

Scientific identity

Sequence: YLRIVQCRSVEGSCGF
Peptide family: Modified C-terminal growth hormone fragment
Entity class: Investigational peptide
Alternative names: hGH fragment 176-191AOD9604AOD 9604Tyr-hGH177-191

Discovery history

Developed from the C-terminal lipolytic region of human growth hormone as an obesity drug intended to influence fat metabolism without full growth-hormone anabolic effects.

Proposed Mechanisms

Lipolysis stimulation (proposed)
preclinical
Lipolysis and fat oxidation →
moderate
C-terminal growth hormone fragment lipid signalling →
moderate

Reported / Studied Uses

Fat loss
Evidence · limited human
Fat Loss / Weight Management
Evidence · low to limited
Obesity / Weight Management
Evidence · insufficient
Body fat reduction
Evidence · insufficient

Human Evidence

Human development reached phase II studies, but the accessible peer-reviewed evidence does not demonstrate clinically meaningful durable weight loss.

Animal Evidence

Rodent studies reported reduced weight gain, increased fat oxidation and altered lipolytic sensitivity.

Species translation to humans is uncertain.

Safety & Unknowns

research-stageinsufficient-human-efficacyproduct-quality-risklong-term-safety-uncertaininvestigationalweight-loss-claims-unprovencompounded-product-riskcounterfeit-riskprohibited-in-sport

Modern long-term safety data are limited. Product quality, injection complications, metabolic effects and use alongside other weight-loss agents require caution.

Regulatory Status

Country	Status	Notes
Australia	Regulated as an unlicensed medicine	TGA restrictions apply.
United States	Not FDA-approved	Research chemical status.

Community Observations

No approved community reports yet. Submit one. Aggregate data is observational only.

References

[1]Ng & Bornstein, 2000s clinical program — AOD9604 trials

Full Disclaimer

This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.

Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.

Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.

↳

Explore further

from the knowledge graph

Mechanisms

Conditions

Related peptides

Sources cited

Advertise here — support independent evidence →